CAJ | 학술논문

目的：探讨切除修复交叉互补基因1（ERCC1）在老年晚期非小细胞肺癌（NSCLC）组织中的表达情况及其临床意义。方法采用免疫组化法检测76例老年晚期NSCLC患者肿瘤组织中ERCC1的表达水平。结果76例老年晚期非小细胞肺癌组织中ERCC1蛋白表达阳性率为36．84％，与患者性别、病理类型、分化程度、临床分期及吸烟指数无关；ERCC1表达阳性组化疗有效率（17．86％）低于阴性组（43．75％），差异有统计学意义（P＜0．05）；ERCC1表达阳性组中位生存期（MST）（10个月）短于阴性组（14个月），但差异无统计学意义（P＞0．05）。结论 ERCC1蛋白表达水平是铂类药物化疗疗效的一个预测指标，有助于非小细胞肺癌个体化化疗方案的制定。
목적：탐토절제수복교차호보기인1（ERCC1）재노년만기비소세포폐암（NSCLC）조직중적표체정황급기림상의의。방법채용면역조화법검측76례노년만기NSCLC환자종류조직중ERCC1적표체수평。결과76례노년만기비소세포폐암조직중ERCC1단백표체양성솔위36．84％，여환자성별、병리류형、분화정도、림상분기급흡연지수무관；ERCC1표체양성조화료유효솔（17．86％）저우음성조（43．75％），차이유통계학의의（P＜0．05）；ERCC1표체양성조중위생존기（MST）（10개월）단우음성조（14개월），단차이무통계학의의（P＞0．05）。결론 ERCC1단백표체수평시박류약물화료료효적일개예측지표，유조우비소세포폐암개체화화료방안적제정。
Objective To study the expression and clinical significance of excision repair cross-complementing group 1 (ERCC1) in elderly patients with advanced non-small cell lung cancer(NSCLC).Methods The expression level of ERCC1 in 76 advanced non-small cell lung cancer(NSCLC)patients were analyzed using immunohistochemical methods.Results The posi-tive ERCC1 protein expression rate was 36.84%among 76 cases,and there was no correlation with gender,pathology,differentia-tion degree,clinical stage and smoking index.The effect of chemotherapy in positive group(17.86%)was lower than that of nega-tive group(43.75%)and the difference was statistically significant(P<0.05).The median survival time in positive group(10 months)was lower than that of negative group(14 months),but the difference was not statistically significant(P>0.05).Conclu-sion The expression level of ERCC1 protein can be a predictive indicator for efficacy of platinum-based chemotherapy,and it is useful for the clinical development of chemotherapy program for NSCLC patients.